18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma.

RATIONALE AND

OBJECTIVES

To develop and validate a preoperative predictive model for occult liver metastases (OLM) in pancreatic ductal adenocarcinoma (PDAC) using fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET) radiomics.

MATERIAL AND

METHODS

This retrospective study included 117 patients with PDAC who underwent preoperative 18F-FDG PET/CT and surgical resection. OLM was defined as liver metastases detected during surgery or within 6 months postoperatively. A fully automated pancreas segmentation strategy was employed, and radiomic features were extracted from PET images. Three machine learning models (logistic regression, multilayer perceptron, and adaptive boosting) were developed and compared to a clinical model incorporating jaundice, metabolic tumor diameter, and maximum standardized uptake value. A fusion model integrating PET radiomic features with clinical variables was subsequently constructed. Model performance was evaluated using receiver operating characteristic curves and decision curve analysis.

RESULTS

Among the 117 patients, 15.4% (n=18) had OLM. The logistic regression radiomics model demonstrated favorable predictive performance (area under the curve [AUC]: 0.936 in the testing cohort) compared to a clinical model based on conventional parameters (AUC: 0.755, P<0.001). Subgroup analyses confirmed robustness across different jaundice statuses, tumor locations, and carbohydrate antigen 19-9 levels. The fusion model that integrates radiomic and clinical features provides a comprehensive tool for preoperative risk stratification, with the potential to guide personalized treatment strategies.

CONCLUSION

In this exploratory study, the 18F-FDG PET radiomics model demonstrates promising predictive performance for OLM in PDAC, outperforming conventional clinical parameters. It shows potential as a valuable tool for preoperative risk stratification and may help inform personalized treatment planning.